CN102985095B - 免疫刺激组合物和疫苗组合物 - Google Patents

免疫刺激组合物和疫苗组合物 Download PDF

Info

Publication number
CN102985095B
CN102985095B CN201180033660.4A CN201180033660A CN102985095B CN 102985095 B CN102985095 B CN 102985095B CN 201180033660 A CN201180033660 A CN 201180033660A CN 102985095 B CN102985095 B CN 102985095B
Authority
CN
China
Prior art keywords
mannan
composition
kda
antigen
oxidized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180033660.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102985095A (zh
Inventor
G.A.彼得斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moral Biology Pharmacy Co Ltd Of Essen
Original Assignee
Moral Biology Pharmacy Co Ltd Of Essen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901997A external-priority patent/AU2010901997A0/en
Application filed by Moral Biology Pharmacy Co Ltd Of Essen filed Critical Moral Biology Pharmacy Co Ltd Of Essen
Publication of CN102985095A publication Critical patent/CN102985095A/zh
Application granted granted Critical
Publication of CN102985095B publication Critical patent/CN102985095B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201180033660.4A 2010-05-10 2011-05-10 免疫刺激组合物和疫苗组合物 Expired - Fee Related CN102985095B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33308610P 2010-05-10 2010-05-10
US61/333,086 2010-05-10
AU2010901997A AU2010901997A0 (en) 2010-05-10 Immunostimulatory and vaccine compositions
AU2010901997 2010-05-10
AU2010904060A AU2010904060A0 (en) 2010-09-09 Immunostimulatory and vaccine compositions
AU2010904060 2010-09-09
PCT/AU2011/000542 WO2011140595A2 (en) 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions

Publications (2)

Publication Number Publication Date
CN102985095A CN102985095A (zh) 2013-03-20
CN102985095B true CN102985095B (zh) 2016-05-18

Family

ID=44914748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180033660.4A Expired - Fee Related CN102985095B (zh) 2010-05-10 2011-05-10 免疫刺激组合物和疫苗组合物

Country Status (9)

Country Link
US (1) US9597392B2 (enExample)
EP (1) EP2574170A4 (enExample)
JP (1) JP6096111B2 (enExample)
CN (1) CN102985095B (enExample)
AU (1) AU2011226992B2 (enExample)
BR (1) BR112012028893A2 (enExample)
CA (1) CA2798856C (enExample)
RU (1) RU2578420C2 (enExample)
WO (1) WO2011140595A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
IN2014CN04251A (enExample) * 2011-11-09 2015-07-17 Ascend Biopharmaceuticals Ltd
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
ES2503516B1 (es) 2013-04-03 2015-09-09 Inmunotek, S.L. Complejo inmunogénico para vacunación y método de obtención
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
EP3286213B1 (en) 2015-04-20 2021-08-04 Etubics Corporation Methods and compositions for combination immunotherapy
EP3474884A4 (en) 2016-06-22 2020-08-19 Alkermes, Inc. COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10
KR20210044805A (ko) 2018-08-06 2021-04-23 닐슨 바이오사이언스, 아이엔씨. 사마귀의 치료
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
AU2022234358A1 (en) * 2021-03-12 2023-10-19 Children's Medical Center Corporation Polysaccharide adjuvants for virus vaccines
CN113616799B (zh) * 2021-07-13 2023-08-29 中国科学院长春应用化学研究所 一种疫苗载体、其制备方法及应用
JPWO2024117232A1 (enExample) * 2022-11-30 2024-06-06

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362951A (en) 1965-12-21 1968-01-09 Farkas Alexander Polysaccharide product derived from the juice of the aloe plant and methods for preparing same
US5308838A (en) 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US4735935A (en) 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US4861761A (en) 1984-06-28 1989-08-29 Dr. Madis Laboratories, Inc. Aloeferon isolation, manufacturing and its applications
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
JPH02501828A (ja) 1987-01-07 1990-06-21 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド プローブ
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE69536091D1 (de) 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
AU3210997A (en) 1996-05-24 1997-12-09 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5824659A (en) 1996-09-04 1998-10-20 Board Of Regents, The University Of Texas System Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation
JP2001507352A (ja) 1996-12-20 2001-06-05 メルク エンド カンパニー インコーポレーテッド 組換えパピローマウイルスワクチンの組成物
WO1998050527A1 (en) 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
AU760669B2 (en) 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
JP2003510094A (ja) 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
JP2003533181A (ja) 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
WO2008037033A1 (en) * 2006-09-29 2008-04-03 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Flu vaccine admixture of mannan and flu antigen
AUPQ797700A0 (en) * 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US7196072B2 (en) 2000-07-10 2007-03-27 University Of Mississippi High molecular weight polysaccharide fraction from Aloe vera with immunostimulatory activity
EP1307213B1 (en) * 2000-08-10 2004-04-28 Ocean Nutrition Canada Ltd. Chlorella preparations exhibiting immunomodulating properties
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
US7906620B2 (en) 2002-08-16 2011-03-15 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2005044861A1 (en) 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
EP1697515A4 (en) * 2003-11-12 2008-02-06 Austin Research Inst CONJUGATE DNA-EXCIPIENT
US20060084629A1 (en) 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
JP2006241020A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 免疫系賦活剤
JP2006241023A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 消化管組織における抗菌ペプチドの発現誘導または産生促進剤
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP2009544291A (ja) 2006-07-25 2009-12-17 フォージー ヴァクシンズ ピーティーワイ エルーティーディー ムチン１（ｍｕｃ１）ｔ細胞エピトープ由来ペプチド含有癌ワクチン
WO2008039432A1 (en) 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway;Vasso Apostolopoulos等;《Eur. J. Immunol》;20001231;第30卷;1714-1723 *

Also Published As

Publication number Publication date
JP2013527854A (ja) 2013-07-04
RU2012152952A (ru) 2014-06-20
EP2574170A4 (en) 2013-11-20
CA2798856A1 (en) 2011-11-17
US9597392B2 (en) 2017-03-21
EP2574170A2 (en) 2013-04-03
US20130251741A1 (en) 2013-09-26
RU2578420C2 (ru) 2016-03-27
CA2798856C (en) 2019-04-23
WO2011140595A3 (en) 2012-01-05
BR112012028893A2 (pt) 2017-12-12
AU2011226992A1 (en) 2011-11-24
WO2011140595A2 (en) 2011-11-17
AU2011226992B2 (en) 2012-03-22
CN102985095A (zh) 2013-03-20
JP6096111B2 (ja) 2017-03-15

Similar Documents

Publication Publication Date Title
CN102985095B (zh) 免疫刺激组合物和疫苗组合物
AU2012334825B2 (en) Immunomodulatory conjugates
JP6825036B2 (ja) 免疫応答のプライミング
JP4184433B2 (ja) 免疫調節のための医薬組成物
CN101678091A (zh) 冷冻干燥的抗原组合物
JP2009524584A (ja) ポリマー−生物製剤送達組成物を構築するための方法
US12478669B1 (en) Herpes zoster mRNA vaccine, preparation method therefor, and use thereof
JP6165182B2 (ja) 免疫アジュバントとしてのグリコシル化により改変された四官能性非イオン性両親媒性ブロックコポリマーの使用
CN118340879B (zh) 复合佐剂、含佐剂的抗肿瘤疫苗、复合佐剂抗肿瘤疫苗及其制备方法与应用
KR20140099828A (ko) 점막 투여용 백신 조성물
Kikuchi Genetically modified dendritic cells for therapeutic immunity
JP7387439B2 (ja) 改良されたｌｉワクチンアジュバント
Zhou et al. Multifunctional lipidated protein carrier with a Built-In adjuvant as a universal vaccine platform potently elevates immunogenicity of weak antigens
Tang et al. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses
JP2005506315A (ja) コレラ毒素およびそのｂサブユニットを用いた抗原提示を促進し免疫応答をモジュレートするための方法
Pappalardo et al. Characterization of a nanovaccine platform based on an α1, 2-mannobiose derivative shows species-non-specific targeting to human, bovine, mouse, and teleost fish dendritic cells
AU2012200183B2 (en) Immunostimulatory and vaccine compositions
EP3473641A1 (en) Nucleic acid-antigen peptide conjugate
Gong et al. Enhancing cell-mediated immunity through dendritic cell activation: the role of Tri-GalNAc-modified PLGA-PEG nanoparticles encapsulating SR717
JP2022036961A (ja) 樹状細胞療法においてｅｘ ｖｉｖｏでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
ES2301418B1 (es) Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotoxica y las formulaciones resultantes.
Gadhave et al. DNA vaccines: A hope full ray in Immunology
US8921534B2 (en) Enhancement of the immune response using CD36-binding domain
TW202506174A (zh) 一種針對ＭＩＣＡ／Ｂ靶點的ｍＲＮＡ腫瘤疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160518

Termination date: 20200510

CF01 Termination of patent right due to non-payment of annual fee